Zydus-Formycon FYB206 Keytruda biosimilar accepted for USFDA review

Regulatory product approvalBusiness Updates View source PDF Explain this filing

ZYDUSLIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.5%Reaction day

₹1134.40

prior close

₹1126.90

announcement price

In-mkt

timing

Nifty 100market+1.5%-1.9% vs market

Pharmaceuticals peers, median of 168sector-0.3%-0.2% vs sector

On the reaction day the stock moved 1.9 pts less than Nifty 100 and 0.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.6

10m

+0.6

15m

+1.0

30m

+0.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.5+1.5-1.9-0.3-0.2

Next day

-0.9+1.1-2.0-0.3-0.5

+0.5+2.4-1.9-1.2+1.7

-1.0+3.0-4.0-1.0+0.0

-1.8+2.0-3.8-2.6+0.8

-1.5+1.4-2.9-4.0+2.5

-0.4+0.2-0.6-6.5+6.1

15d

—————

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 168Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

USFDA has accepted the Biologics License Application for FYB206, a proposed biosimilar to Keytruda (pembrolizumab), for review. This is the first publicly announced Keytruda biosimilar accepted by USFDA. Zydus holds exclusive US and Canada commercialization rights. Keytruda had worldwide sales of USD 31.7 billion in 2025. BLA was filed in Q3 2026; FDA decision expected by Q3 2027.

Likely market impact

Positive regulatory milestone for Zydus oncology biosimilars portfolio; FDA decision expected by Q3 2027, approval still pending.